FDA 483 OBSERVATION · #127 OF 1,923 MOST-CITED

Lack of quality control unit

FDA cited this observation 239 times across 224 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

What this grouping is not

An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.

BY PROGRAM AREA

Drugs239

BY FISCAL YEAR

FY202613

FY202528

FY202424

FY202313

FY202220

FY20218

FY202013

FY201931

FY201829

FY201735

FY201625

What this observation means, and how to comply

SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.

21 CFR 211.22

The firm has not established a quality control unit with the responsibility and authority required by §211.22 — the unit that approves or rejects components, drug product containers, in-process materials, and finished products, and that reviews production records and approves procedures affecting quality.

Why FDA writes it — The quality control unit is the independent authority that stands between production and release. Without a functioning QCU — or where production overrides it — FDA has no assurance that anyone with authority and independence is actually deciding what ships, so defective product can reach patients unchecked.

HOW TO COMPLY

Formally establish a quality control unit with written responsibility and authority to approve or reject at every stage per §211.22.
Ensure organizational independence so the QCU can reject product without being overruled by production or commercial pressure.
Give the QCU adequate laboratory facilities or controlled access to test components, in-process, and finished product.
Require QCU review and approval of all procedures and specifications impacting identity, strength, quality, and purity.

WHY FIRMS GET CITED

In small or new firms one person wears both production and quality hats, destroying QCU independence.
The QCU exists on the org chart but lacks the authority to actually halt release when it objects.

PROFESSIONAL · REMEDIATION PLAYBOOK · SPEQ SYNTHESIS

How to close this finding — and stop it recurring

CHECKING ACCESS

Checking your Professional access…

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 5.8× the rate of the average FDA-cited firm (44.6% vs 7.8%), across 224 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your Professional access…